Yasmin Rahim

1.4k total citations
17 papers, 542 citations indexed

About

Yasmin Rahim is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Yasmin Rahim has authored 17 papers receiving a total of 542 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 5 papers in Epidemiology. Recurrent topics in Yasmin Rahim's work include Bone health and treatments (5 papers), Radiopharmaceutical Chemistry and Applications (4 papers) and Bladder and Urothelial Cancer Treatments (3 papers). Yasmin Rahim is often cited by papers focused on Bone health and treatments (5 papers), Radiopharmaceutical Chemistry and Applications (4 papers) and Bladder and Urothelial Cancer Treatments (3 papers). Yasmin Rahim collaborates with scholars based in Canada, Pakistan and Australia. Yasmin Rahim's co-authors include Allan Lipton, Karim Fizazi, Guozhi Gao, Ling Wu, Winnie Sohn, Jean‐Jacques Body, Julie R. Gralow, Xavier Mariette, Susie Jun and Jean‐François Pouliot and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Urology and Canadian Medical Association Journal.

In The Last Decade

Yasmin Rahim

16 papers receiving 533 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yasmin Rahim Canada 9 439 188 165 115 111 17 542
N.J.R. George United Kingdom 14 241 0.5× 123 0.7× 394 2.4× 121 1.1× 88 0.8× 23 711
Vassiliki Koutsoukou Greece 7 879 2.0× 82 0.4× 133 0.8× 80 0.7× 64 0.6× 8 972
Victor Vishwanath Iyer Denmark 12 147 0.3× 214 1.1× 159 1.0× 32 0.3× 21 0.2× 21 506
Nicolai Leonhartsberger Austria 14 69 0.2× 43 0.2× 150 0.9× 244 2.1× 128 1.2× 34 537
Naoya Ishibashi Japan 10 127 0.3× 79 0.4× 96 0.6× 97 0.8× 43 0.4× 72 377
C. Andreadis Greece 8 563 1.3× 48 0.3× 76 0.5× 74 0.6× 36 0.3× 18 660
Maria Silvia Spinelli Italy 13 233 0.5× 58 0.3× 168 1.0× 448 3.9× 13 0.1× 25 614
W. Koestler Austria 12 150 0.3× 62 0.3× 58 0.4× 468 4.1× 80 0.7× 26 707
H. Gamm Germany 9 250 0.6× 40 0.2× 41 0.2× 33 0.3× 81 0.7× 17 478
Hidenobu Matsuzaki Japan 18 162 0.4× 240 1.3× 72 0.4× 312 2.7× 80 0.7× 59 828

Countries citing papers authored by Yasmin Rahim

Since Specialization
Citations

This map shows the geographic impact of Yasmin Rahim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yasmin Rahim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yasmin Rahim more than expected).

Fields of papers citing papers by Yasmin Rahim

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yasmin Rahim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yasmin Rahim. The network helps show where Yasmin Rahim may publish in the future.

Co-authorship network of co-authors of Yasmin Rahim

This figure shows the co-authorship network connecting the top 25 collaborators of Yasmin Rahim. A scholar is included among the top collaborators of Yasmin Rahim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yasmin Rahim. Yasmin Rahim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
2.
3.
Sridhar, Srikala S., Normand Blais, Ben Tran, et al.. (2020). Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer. JAMA Oncology. 6(11). 1751–1751. 25 indexed citations
4.
Rahim, Yasmin, et al.. (2019). Primary pulmonary plasmacytoma presenting with rare IgG lambda monoclonal gammopathy. BMJ Case Reports. 12(3). e227514–e227514. 4 indexed citations
5.
Simos, Demetrios, et al.. (2019). Clinical practice patterns on the use of adjuvant bisphosphonate for early breast cancer: A Canadian perspective.. Journal of Clinical Oncology. 37(15_suppl). e12002–e12002. 1 indexed citations
6.
Sridhar, Srikala S., Normand Blais, Ben Tran, et al.. (2018). Cctg BL12: Randomized phase II trial comparing nab-paclitaxel (Nab-P) to paclitaxel (P) in patients (pts) with advanced urothelial cancer progressing on or after a platinum containing regimen (NCT02033993).. Journal of Clinical Oncology. 36(15_suppl). 4505–4505. 6 indexed citations
7.
Rahim, Yasmin, et al.. (2018). Invasive mediastinal aspergillosis presenting as superior vena cava syndrome in an immunocompetent patient. BMJ Case Reports. 2018. bcr–2018. 1 indexed citations
8.
9.
Ginsburg, Ophira, Timothy P. Hanna, Theodore A. Vandenberg, et al.. (2012). The global cancer epidemic: opportunities for Canada in low- and middle-income countries. Canadian Medical Association Journal. 184(15). 1699–1704. 10 indexed citations
10.
Fizazi, Karim, Allan Lipton, Xavier Mariette, et al.. (2009). Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates. Journal of Clinical Oncology. 27(10). 1564–1571. 388 indexed citations
11.
12.
13.
Gregori, Darío, Cecilia Scarinzi, Paola Berchialla, et al.. (2007). The cost of foreign body injuries in the upper aero-digestive tract: Need for a change from a clinical to a public health perspective?. International Journal of Pediatric Otorhinolaryngology. 71(9). 1391–1398. 17 indexed citations
14.
15.
Leighl, Natasha B., Glenwood Goss, Ronald L. Burkes, et al.. (2006). Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer. Lung Cancer. 52(3). 327–332. 15 indexed citations
16.
Suarez, T., Karim Fizazi, Yasmin Rahim, et al.. (2006). A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. Journal of Clinical Oncology. 24(18_suppl). 8562–8562. 11 indexed citations
17.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by N.J.R. George Breakdown of academic impact, for papers by Vassiliki Koutsoukou Breakdown of academic impact, for papers by Victor Vishwanath Iyer Breakdown of academic impact, for papers by Nicolai Leonhartsberger Breakdown of academic impact, for papers by Naoya Ishibashi Breakdown of academic impact, for papers by C. Andreadis Breakdown of academic impact, for papers by Maria Silvia Spinelli Breakdown of academic impact, for papers by W. Koestler Breakdown of academic impact, for papers by H. Gamm Breakdown of academic impact, for papers by Hidenobu Matsuzaki
Rankless by CCL
2026